A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.
| Autor: | Lin, Thomas S., Heerema, Nyla A. *, Swenor, Jennifer *, Lucas, Margaret S. *, Moran, Mollie E. *, Cheney, Carolyn M. *, Lucas, David M. *, Young, Donn *, Caligiuri, Michael A., Grever, Michael R., Byrd, John C. |
|---|---|
| Zdroj: | In Blood 16 November 2004 104(11):3469-3469 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|